Table 2.
Optimal Gag MA and CA epitopes recognized by CTL from EIAV-infected horses
| Horse no. | Optimal epitopes | Gag location (name) | Epitope cluster | Avidity (nM) |
|---|---|---|---|---|
| H593 | DCTSEEMNAF | CA 47–56 (DF10) | Non EC | >1000 |
| KSEGHPQEISKF | CA 173–184 (KF12) | EC3 | 3.7 | |
| H596 | KMGLQINNVVDG | MA 86–97 (KG12) | EC2 | >1000 |
| YPEFVDRLLSQI | CA 161–172 (YI12) | EC3 | 2.7 | |
| FVDRLLSQIKSEa | CA 164–175 (FE12) | EC3 | 9.9 | |
| IKSEGHPQEI | CA 172–181 (II10) | EC3 | 0.9 | |
| H601 | GSQKLTTGNCNW | MA 21–32 (GW12) | EC1 | 10.9 |
| H610 | YEKKTANK | MA 108–115 (YK8) | EC2 | >1000 |
| MRHLRPEDTL | CA 202–211 (ML10) | EC4 | >1000 | |
| RPEDTLEEKMYA | CA 206–217 (RA12) | EC4 | >1000 | |
| EDTLEEKMYACR | CA 208–219 (ER12) | EC4 | >1000 | |
| YACRDIGTTKQK | CA 216–227 (YK12) | EC4 | >1000 | |
| H614 | DRLLSQIKSE | CA 166–175 (DE10) | EC3 | >1000 |
| H629 | NEECRNAMRHLR | CA 195–206 (NR12) | EC4 | >1000 |
| IGTTKQKMM | CA 221–229 (IM9) | EC4 | >1000 | |
| H631 | KALKKLEKV | MA 9–17 (KV9) | EC1 | 71.3 |
| RAKYEKKTANK | MA 105–115 (RK11) | EC2 | 7.9 | |
| A2140 | GSQKLTTGNCNW | MA 21–32 (GW12) | EC1 | 3.9 |
| A2147 | RTWWAISAVK | MA 77–86 (RK10) | EC2 | >1000 |
| WWAISAVKMGL | MA 79–89 (WL11) | EC2 | >1000 | |
| WAISAVKMGLQI | MA 80–91 (WI12) | EC2 | >1000 | |
| GIKVMIGKPKAQ | CA 140–151 (GQ12) | Non EC | >1000 | |
| PEFVDRLLSQ | CA 162–171 (PQ10) | EC3 | >1000 | |
| RLLSQIKSEG | CA 167–176 (RG10) | EC3 | >1000 | |
| TLTIQNANEECRb | CA 188–199 (TR12) | EC4 | >1000 |
a
Peptide EFVDRLLSQIKS was also recognized by CTL from H596 with high functional avidity (10 nM) but was considered the same epitope as FVDRLLSQIKSE.
b
Only C-terminal eight amino acid residues of TLTIQNANEECR were in EC4 (Chung et al., 2004).